Vienna Convention Neuronetics, Inc. Neuronetics, Research Proposal

Length: 8 pages Sources: 3 Subject: Business Type: Research Proposal Paper: #88011106 Related Topics: Neuron, Global Expansion, Solution Focused Therapy, Expansion
Excerpt from Research Proposal :



Phase one means building a strong foundation. The benefits of a strong foundation will be felt for many years to come. Rapid expansion is good, but not if it means sacrificing quality and support. Customers will talk about the NeuroStar to others. This best advertising that the company can have is to make certain that customers and patients have a positive experience not only with the device, but with the company and staff as well. The company needs to treat its customers the way they wish to be treated themselves. This is the philosophy that will result in building a strong base. This initial phase may take as long as two years.

Phase Two

Once a strong foundation has been established and sales begin to increase as a result of initial marketing and customer support efforts, then the business can focus on picking up the pace. It will be at least five years for the market to mature and at least ten for it to become saturated to the point where further expansion is needed to sustain growth. The market is young, which means years of steady growth. During this phase focus will be on building a client base from primary market targets, such as clinicians and treatment facilities. After it is estimated that nearly 70% of this market has been captured or approached, marketing will begin to focus on secondary marketing targets such as general hospitals and educational facilities.

The goal is to continue to expand phase two for as long as possible. Phase two represents a phase of solid growth. The market will continue to expand and develop. During this phase measures should be taken to expand the current offerings. Actions that will help to maintain market growth include development, licensing, and marketing of new improved editions of NeuroStar TMS and the development of similar devices for other disorders. The product pipeline should continue to expand during this phase. This will allow sales personnel to approach primary targets that already own a unit to attempt to get them to upgrade, or to try a different device. This marketing strategy will allow the company to postpone maturation of the market for as long as possible.

When it is estimated that approximately 70% of the secondary target market if saturated, it will then be time to consider seeking expansion into the global market. The process for obtaining regulatory approval in desirable targets overseas will begin. Culturally...

...

Continued expansion of the product line will ensure the ability to maintain sales growth. Expanding into the global market could be the key to long-term sustainability once the domestic market is nearly tapped out. It is not expected that this stage will occur before 10-15 years. With the introduction of new products and improvements on old ones, Neuronetics may be able to avoid maturation of the market well into the long-term future.

Conclusion

Neuronetics represents an exciting opportunity for the entrepreneur with long-term vision. The worst mistake that the company could make would be to expand too rapidly. They may experience rapid growth in the future, but they are more likely to make mistakes that could cost them their reputation and customer base in the future. This situation must be avoided in order to preserve the longevity of the company in the future.

Neuronetics, Inc. is an innovative company with innovative ideas. Their key strength lies in the ability to establish themselves in the market early on in the game. Their strengths outweigh their weaknesses. They have many opportunities that have presented themselves, and it is expected that they will be able to overcome perceived weaknesses and threats to their success. However, these threats can only be overcome if upper management has the foresight to anticipate them.

Neuronetics, Inc. is a pioneer in the use of magnetics for the treatment of conditions using magnetic fields to stimulate neural response. Medical magnets have been on the market for many years with varying degrees of success, but these devices never made it into the clinical setting. Neuronetics, Inc. has been able to do what others only wished they could do. This small success is only the beginning of a long chain of success for the company in the future.

References

Fitzgerald, P., Fountain, S., & Daskalakis, Z. (2006). A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition. Clinical Neurophysiology 117 (12):

2584 -- 96. doi:10.1016/j.clinph.2006.06.712. PMID 16890483.

Baldauf, S. (2009). Brain Stimulation: Transcranial Magnetic Stimulation. No surgery required -- magnetic pulses treat symptoms of depression and other conditions

Posted July 15, 2009 U.S. News. Retrieved July 17, 2009 from http://health.usnews.com/articles/health/brain-and-behavior/2009/07/15/brain-stimulation-transcranial-magnetic-stimulation.html

Neuronetics, Inc. (2009). About. Retrieved July 17, 2009 from http://www.neuronetics.com/about-profile.aspx

Zwillich, T. (2007). Device for Depression Criticized. January 29, 2007. National Research

Center for Women & Families. Retrieved July 17, 2009…

Sources Used in Documents:

References

Fitzgerald, P., Fountain, S., & Daskalakis, Z. (2006). A comprehensive review of the effects of rTMS on motor cortical excitability and inhibition. Clinical Neurophysiology 117 (12):

2584 -- 96. doi:10.1016/j.clinph.2006.06.712. PMID 16890483.

Baldauf, S. (2009). Brain Stimulation: Transcranial Magnetic Stimulation. No surgery required -- magnetic pulses treat symptoms of depression and other conditions

Posted July 15, 2009 U.S. News. Retrieved July 17, 2009 from http://health.usnews.com/articles/health/brain-and-behavior/2009/07/15/brain-stimulation-transcranial-magnetic-stimulation.html


Cite this Document:

"Vienna Convention Neuronetics Inc Neuronetics " (2009, July 17) Retrieved September 25, 2021, from
https://www.paperdue.com/essay/vienna-convention-neuronetics-inc-neuronetics-20524

"Vienna Convention Neuronetics Inc Neuronetics " 17 July 2009. Web.25 September. 2021. <
https://www.paperdue.com/essay/vienna-convention-neuronetics-inc-neuronetics-20524>

"Vienna Convention Neuronetics Inc Neuronetics ", 17 July 2009, Accessed.25 September. 2021,
https://www.paperdue.com/essay/vienna-convention-neuronetics-inc-neuronetics-20524

Purpose of Paperdue.com

The documents we provide are to be used as a sample, template, outline, guideline in helping you write your own paper, not to be used for academic credit. All users must abide by our "Student Honor Code" or you will be restricted access to our website.

Related Documents
FDA: Center for Drug Evaluation and Research
Words: 1105 Length: 3 Pages Topic: Health - Safety Paper #: 20976543

FDA: Center for Drug Evaluation and Research (CDER) And Over-the-counter Weight Loss Medications Obesity is one of the most serious epidemics facing the American public. "Over two-thirds of adults in the United States are overweight or obese, and over one-third are obese" (Overweight and obesity statistics, 2012, WIN). To address concerns about obesity, many adults turn to over-the-counter medications like dietary supplements that promise the user easy weight loss. The medications usually

FDA Classification the FDA Is
Words: 577 Length: 2 Pages Topic: Education - Computers Paper #: 36046999

Given that there is no expectation of substantial equivalence, the following process will need to be undertaken. The 510(K) that needs to be submitted is the Traditional. A Special is for modifications to products that already have 510(k) approval, so that does not apply in this case. An Abbreviated 510(K) applies when a product is approved for this process by the FDA. There is little explanation on the FDA website

FDA Health Policy on Intravesical
Words: 3065 Length: 10 Pages Topic: Disease Paper #: 60502002

Phase II consists of efficacy trials of the drug, which are tested on volunteers of the target population. When everything goes right, the drug manufacturer discusses the development process, continued human testing, other concerns and protocols for phase III with the FDA. Phase III is the more extensive. It is at this time that the manufacture can work for the accelerated development and review of the drug. Treatment IND

FDA and Gene Therapy
Words: 892 Length: 2 Pages Topic: Genetics Paper #: 92639038

Gene Therapy FDA Ethics can be considered to come from personal values. From both a medical and a business perspective, ethics are the reasons that some news stories should be followed from beginning to end and all in between. "On Sunday morning, 23 February 1997, the world awoke to a technological advance that shook the foundations of biology and philosophy. On that day, we were introduced to Dolly, a 6-month-old lamb that

FDA Homeopathics
Words: 748 Length: 2 Pages Topic: Medicine Paper #: 55923849

Divisions of the FDA The FDA is in charge of the regulation of pharmaceutical drugs and medical devices, as part of its mandate to safeguard the U.S. health care system. One unit for this is the Center for Devices and Radiological Health (CDRH), which approves medical devices. The unit that approves drugs is the Center for Drug Evaluation and Research (CDER). There is also the Center for Biologics Evaluation and Research

FDA and Its Regulatory Powers
Words: 1619 Length: 4 Pages Topic: Business - Law Paper #: 20919152

Administrative Law REGULATING STEM CELL THERAPY Administrative Agency: Food and Drug Administration Article 1 Section 1 of the federal Constitution creates administrative agencies, which are law-making entities but with limited powers (USLegal, 2014). The rules and regulations created by an administrative agency are lawfully enforceable. It assists in the faster management of cases and is, therefore, a big help to U.S. courts. The administrative process is also a valuable resource for other important